Developer docs
API playgroundTry for free, no card

Search company profiles

Abdera Therapeutics

Full company profile

uuid0000bg4

Namestring
Abdera Therapeutics
Legal namestring
Abdera Therapeutics
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Abdera Therapeutics is a Vancouver-based, privately held oncology company founded in 2021 that develops targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. The company's lead programs are antibody-based radiopharmaceuticals built on its proprietary ROVEr platform, which is engineered to optimize radioisotope delivery to tumor cells. The disclosed pipeline centers on ABD-147, a DLL3-targeted radiotherapeutic for small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), and ABD-320, a pan-cancer radiotherapeutic candidate.

The ROVEr platform is the core technology asset and the basis for differentiation versus other TAT developers such as Ratio Therapeutics and Perspective Therapeutics. Abdera operates pre-clinically as of early 2026 and has no commercial products, pricing, or distribution infrastructure; the intended commercial model aligns with licensing/royalty economics typical of asset-light radiopharma developers. The company emerged publicly in April 2023 with a $142 million combined Series A and Series B financing led by venBio Partners, with Versant Ventures, Viking Global Investors, RTW Investments, Qiming Venture Partners USA, Amplitude Venture Capital, and Northview LifeSciences participating, following a roughly $6.3 million seed in 2021.

Go-to-market is presently limited to scientific and investor-facing channels, including pipeline presentations at industry conferences such as the 44th Annual J.P. Morgan Healthcare Conference in January 2026 by CEO Lori Lyons-Williams. The company has 51–100 employees and remains an independent private entity with no disclosed parent, subsidiaries, partnerships, M&A activity, or regulatory actions on record.

Short descriptiontext

Abdera Therapeutics is a Vancouver-based, privately held oncology biotech developing targeted alpha radiopharmaceuticals using its proprietary ROVEr antibody platform to treat DLL3-expressing cancers, with lead candidate ABD-147 in small cell lung cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
targeted radiopharmaceuticals, oncology drug development, antibody-radionuclide conjugates, targeted alpha therapy, DLL3 cancer therapeutics
Industry3 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Radiopharmaceuticals
Social media profiles2 records
Revenue model1 record
1Radiopharmaceutical Development
TypeLicensing Royalties
Description

Pre-commercial stage company developing antibody-based radiopharmaceuticals for cancer treatment. No revenue currently generated as products are in pre-clinical stages.

abderatx.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Abdera Therapeutics develops antibody-based radiopharmaceuticals for the treatment of cancer, leveraging its proprietary ROVEr platform to optimize radioisotope delivery to tumor cells. The company's pipeline includes ABD-147, which targets DLL3 in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), and ABD-320, a pan-cancer radiotherapeutic candidate. The company is currently in the pre-clinical stage of drug development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • DLL3-targeted therapy development for SCLC and LCNEC
Product overview1 text field

Abdera Therapeutics is a biotech company developing targeted radiopharmaceuticals for cancer treatment using its proprietary ROVEr platform. The company's lead pipeline includes ABD-147 (targeting DLL3 for small cell lung cancer and LCNEC) and ABD-320 (with pan-cancer potential), both antibody-based radiotherapeutics designed to optimize radioisotope delivery to tumor cells.

Product and service3 records
1ROVEr Platform
CategoryProprietary drug discovery platform
Description

A proprietary technology platform for developing antibody-based radiopharmaceuticals for cancer treatment, designed to optimize radioisotope delivery to tumor cells. It underpins Abdera's pipeline of antibody-radionuclide conjugates.

2ABD-147
CategoryPipeline candidate (oncology radiopharmaceutical)
Description

A radiotherapeutic candidate in Abdera's pipeline targeting DLL3 for the treatment of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). It is being developed using the company's ROVEr platform to optimize antibody-based radioisotope delivery.

3ABD-320
CategoryPipeline candidate (oncology radiopharmaceutical)
Description

A radiotherapeutic candidate with pan-cancer potential, in development for multiple oncology indications beyond SCLC and LCNEC as part of Abdera's pipeline of antibody-based targeted radiopharmaceuticals built on the ROVEr platform.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Owner of Pluvicto and Lutathera, the commercial benchmarks in radioligand therapy. The dominant incumbent whose commercial traction and pipeline expansion define the strategic context for every peer including Abdera.

TypeOthers
Description

Manufacturer and supplier of medical radioisotopes (including actinium-225) used in targeted radionuclide therapy. An ecosystem enabler whose supply chain underpins the entire radiopharmaceutical class including Abdera's pipeline.

TypeBroad incumbent
Description

Radiopharmaceutical-focused specialty company with approved diagnostic and therapeutic agents (e.g., PNT2002 prostate cancer program). A broad incumbent in the targeted radiopharmaceutical space.

TypeDirect peer
Description

Pre-clinical-stage radiopharmaceutical company developing targeted alpha therapies for solid tumors. Explicitly named as a same-stage competitor to Abdera with overlapping therapeutic focus.

TypeEmerging player
Description

Radiopharmaceutical-focused oncology platform company acquired by Novartis in 2024 for $1 billion upfront. Develops peptide-based radioligand therapies; comparable as a platform-approach targeted radiopharmaceutical developer.

TypeBroad incumbent
Description

Developer of Xofigo (radium-223) and active builder of a broader targeted radionuclide therapy pipeline. A broad incumbent with strategic interest in TATs comparable to Abdera's approach.

TypeDirect peer
Description

Pre-clinical developer of radiopharmaceuticals (including Radioligand Therapy platform technologies) targeting oncology. Explicitly cited alongside Abdera at the same development stage with overlapping lung cancer and pan-tumor ambitions.

TypeDirect peer
Description

Pre-clinical/clinical-stage developer of actinium-225 alpha-emitting radiopharmaceuticals for oncology. Acquired by Bristol Myers Squibb for $4.1 billion; the most direct comparable for Abdera's TAT platform.

TypeBroad incumbent
Description

Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic radiopharmaceuticals across oncology indications. A broader incumbent with overlapping development priorities.

TypeEmerging player
Description

Clinical-stage radiopharmaceutical company developing targeted alpha therapy for PSMA-expressing cancers; acquired by Eli Lilly in 2024. Comparable as a TAT-focused oncology developer with similar therapeutic modality to Abdera.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abdera Therapeutics

Oncology Radiopharmaceuticalsabderatherapeutics.com

Abdera Therapeutics is a Vancouver-based, privately held oncology biotech developing targeted alpha radiopharmaceuticals using its proprietary ROVEr antibody platform to treat DLL3-expressing cancers, with lead candidate ABD-147 in small cell lung cancer.

What Abdera Therapeutics does

Abdera Therapeutics is a Vancouver-based, privately held oncology company founded in 2021 that develops targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. The company's lead programs are antibody-based radiopharmaceuticals built on its proprietary ROVEr platform, which is engineered to optimize radioisotope delivery to tumor cells. The disclosed pipeline centers on ABD-147, a DLL3-targeted radiotherapeutic for small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), and ABD-320, a pan-cancer radiotherapeutic candidate.

The ROVEr platform is the core technology asset and the basis for differentiation versus other TAT developers such as Ratio Therapeutics and Perspective Therapeutics. Abdera operates pre-clinically as of early 2026 and has no commercial products, pricing, or distribution infrastructure; the intended commercial model aligns with licensing/royalty economics typical of asset-light radiopharma developers. The company emerged publicly in April 2023 with a $142 million combined Series A and Series B financing led by venBio Partners, with Versant Ventures, Viking Global Investors, RTW Investments, Qiming Venture Partners USA, Amplitude Venture Capital, and Northview LifeSciences participating, following a roughly $6.3 million seed in 2021.

Go-to-market is presently limited to scientific and investor-facing channels, including pipeline presentations at industry conferences such as the 44th Annual J.P. Morgan Healthcare Conference in January 2026 by CEO Lori Lyons-Williams. The company has 51–100 employees and remains an independent private entity with no disclosed parent, subsidiaries, partnerships, M&A activity, or regulatory actions on record.

Abdera Therapeutics firmographics

Firmographics
Name
Abdera Therapeutics
Legal name
Abdera Therapeutics
Website
https://abderatherapeutics.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
Abdera Therapeutics is a Vancouver-based, privately held oncology biotech developing targeted alpha radiopharmaceuticals using its proprietary ROVEr antibody platform to treat DLL3-expressing cancers, with lead candidate ABD-147 in small cell lung cancer.
Ownership category
akta.pro rank

Abdera Therapeutics industry classification

Industry
Product category
Oncology Radiopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Targeted radiopharmaceuticals
  • Oncology drug development
  • Antibody-radionuclide conjugates
  • Targeted alpha therapy
  • DLL3 cancer therapeutics

Where Abdera Therapeutics is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Markets served

Abdera Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Radiopharmaceutical Development: Pre-commercial stage company developing antibody-based radiopharmaceuticals for cancer treatment. No revenue currently generated as products are in pre-clinical stages.

Marketing channels1 record

Abdera Therapeutics product offering

Product offering

Core offering

Abdera Therapeutics develops antibody-based radiopharmaceuticals for the treatment of cancer, leveraging its proprietary ROVEr platform to optimize radioisotope delivery to tumor cells. The company's pipeline includes ABD-147, which targets DLL3 in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), and ABD-320, a pan-cancer radiotherapeutic candidate. The company is currently in the pre-clinical stage of drug development.

Product overview

Abdera Therapeutics is a biotech company developing targeted radiopharmaceuticals for cancer treatment using its proprietary ROVEr platform. The company's lead pipeline includes ABD-147 (targeting DLL3 for small cell lung cancer and LCNEC) and ABD-320 (with pan-cancer potential), both antibody-based radiotherapeutics designed to optimize radioisotope delivery to tumor cells.

Differentiator

Problem solved

Functional benefit

Products and services

  • ROVEr Platform A proprietary technology platform for developing antibody-based radiopharmaceuticals for cancer treatment, designed to optimize radioisotope delivery to tumor cells. It underpins Abdera's pipeline of antibody-radionuclide conjugates.
  • ABD-147 A radiotherapeutic candidate in Abdera's pipeline targeting DLL3 for the treatment of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). It is being developed using the company's ROVEr platform to optimize antibody-based radioisotope delivery.
  • ABD-320 A radiotherapeutic candidate with pan-cancer potential, in development for multiple oncology indications beyond SCLC and LCNEC as part of Abdera's pipeline of antibody-based targeted radiopharmaceuticals built on the ROVEr platform.

Quantifiable outcome

  • DLL3-targeted therapy development for SCLC and LCNEC

Companies that use Abdera Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Abdera Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Abdera Therapeutics partnerships and signals

Strategic signal

Scale indicators2 records

Expansion highlights4 records

Abdera Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Novartis (Radioligand Therapy): Owner of Pluvicto and Lutathera, the commercial benchmarks in radioligand therapy. The dominant incumbent whose commercial traction and pipeline expansion define the strategic context for every peer including Abdera.
  • Lantheus Holdings: Radiopharmaceutical-focused specialty company with approved diagnostic and therapeutic agents (e.g., PNT2002 prostate cancer program). A broad incumbent in the targeted radiopharmaceutical space.
  • Bayer (Radiopharmaceuticals): Developer of Xofigo (radium-223) and active builder of a broader targeted radionuclide therapy pipeline. A broad incumbent with strategic interest in TATs comparable to Abdera's approach.
  • Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic radiopharmaceuticals across oncology indications. A broader incumbent with overlapping development priorities.

Others

  • ITM Isotope Technologies Munich: Manufacturer and supplier of medical radioisotopes (including actinium-225) used in targeted radionuclide therapy. An ecosystem enabler whose supply chain underpins the entire radiopharmaceutical class including Abdera's pipeline.

Direct peers

  • Perspective Therapeutics: Pre-clinical-stage radiopharmaceutical company developing targeted alpha therapies for solid tumors. Explicitly named as a same-stage competitor to Abdera with overlapping therapeutic focus.
  • Ratio Therapeutics: Pre-clinical developer of radiopharmaceuticals (including Radioligand Therapy platform technologies) targeting oncology. Explicitly cited alongside Abdera at the same development stage with overlapping lung cancer and pan-tumor ambitions.
  • RayzeBio: Pre-clinical/clinical-stage developer of actinium-225 alpha-emitting radiopharmaceuticals for oncology. Acquired by Bristol Myers Squibb for $4.1 billion; the most direct comparable for Abdera's TAT platform.

Emerging players

  • Mariana Oncology: Radiopharmaceutical-focused oncology platform company acquired by Novartis in 2024 for $1 billion upfront. Develops peptide-based radioligand therapies; comparable as a platform-approach targeted radiopharmaceutical developer.
  • Convergent Therapeutics: Clinical-stage radiopharmaceutical company developing targeted alpha therapy for PSMA-expressing cancers; acquired by Eli Lilly in 2024. Comparable as a TAT-focused oncology developer with similar therapeutic modality to Abdera.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Abdera Therapeutics social profiles

Digital presence

Abdera Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abdera Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Abdera Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abdera Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abdera Therapeutics

What does Abdera Therapeutics do?

Abdera Therapeutics develops antibody-based radiopharmaceuticals for the treatment of cancer, leveraging its proprietary ROVEr platform to optimize radioisotope delivery to tumor cells. The company's pipeline includes ABD-147, which targets DLL3 in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), and ABD-320, a pan-cancer radiotherapeutic candidate. The company is currently in the pre-clinical stage of drug development.

Is Abdera Therapeutics a public or private company?

Abdera Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Abdera Therapeutics founded?

Abdera Therapeutics was founded in 2023. It employs 51 to 100 people.

Where is Abdera Therapeutics based?

Abdera Therapeutics is headquartered in Vancouver, Canada, in the North America region.

How does Abdera Therapeutics make money?

One revenue line is on record: radiopharmaceutical Development.

Who are Abdera Therapeutics's main competitors?

Broad incumbents on record are Novartis (Radioligand Therapy), Lantheus Holdings, Bayer (Radiopharmaceuticals) and Telix Pharmaceuticals. ITM Isotope Technologies Munich is listed as an others. Direct peers are Perspective Therapeutics, Ratio Therapeutics and RayzeBio. Emerging players are Mariana Oncology and Convergent Therapeutics.

Does Abdera Therapeutics have an API?

No public API is recorded for Abdera Therapeutics.

What industry is Abdera Therapeutics in?

Abdera Therapeutics's product category is Oncology Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewsfileDefence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical ProgramsDefence Therapeutics appointed Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs to strengthen its leadership in developing next-generation precision oncology therapeutics. The appointment follows the recent hiring of President and CEO Dr. Amie Phinney and the opening of a new office at McMaster Innovation Park, positioning the company for accelerated development of its Accum® platform. Dr. Simms brings over 20 years of experience from previous roles at Fusion Pharmaceuticals and Abdera Therapeutics.EIN PresswireAbdera Therapeutics to auction off extremely late-model Agilent HPLC Systems, Mass Spectrometers, R&D InstrumentsAbdera Therapeutics will auction its R&D instruments online on June 16th at 10am PST in Vancouver, BC. The auction includes Agilent HPLC systems, mass spectrometers, and other equipment from Fisher, Sartorius, and others. The sale is conducted by Silicon Valley Disposition and Heritage Global Partners.pharmaphorumJPM: The calm before the storm for radiotherapeuticsAt the Sachs Oncology Forum ahead of the JP Morgan Healthcare Conference, radiopharma leaders discussed the present and future of radioligand therapies (RLTs) for cancer treatment, with industry projections indicating the market could reach tens of billions of dollars. Novartis (the only company with approved RLT therapies) and RayzeBio (recently acquired by Bristol Myers Squibb for $4.1 billion) are positioned as market leaders, while other companies like Ratio Therapeutics, Perspective Therapeutics, and Abdera Therapeutics are in pre-clinical stages. The panel identified key challenges including radioactive isotope supply constraints, short half-life logistics, and PET imaging capacity bottlenecks that must be resolved before mass market adoption.PR NewswireNeuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsightDelveInsight published a market insights report projecting the neuroendocrine carcinoma treatment market to grow through 2036 in major markets including the US, EU4 countries, UK, and Japan, driven by rising disease prevalence and improved diagnostic capabilities. Multiple pharmaceutical companies including Boehringer Ingelheim, Oxford BioTherapeutics, Merck, Daiichi Sankyo, Zai Lab, MediLink Therapeutics, Phanes Therapeutics, Legend Biotech, Novartis, Abdera Therapeutics, and Amgen are advancing DLL3-targeted therapies, antibody-drug conjugates, and bispecific T-cell engagers through clinical trials. Key clinical developments include Boehringer Ingelheim's Phase II DAREON-5 trial data presentation at ESMO 2025 and Legend Biotech's Phase I dose-escalation study results presented at ASCO 2025.Business Wire BlogAbdera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13Abdera Therapeutics announced that President and CEO Lori Lyons-Williams will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will cover the company's pipeline including ABD-147, a Phase 1 clinical trial asset targeting DLL3 for small cell lung cancer and large cell neuroendocrine carcinoma, and ABD-320 targeting 5T4 with pan-cancer potential on track for 2026 clinical development. Abdera is a clinical-stage biopharmaceutical company leveraging its proprietary ROVEr platform to develop tunable precision radiopharmaceuticals for cancer treatment.Business Wire BlogAbdera Therapeutics to Present Key Updates on its Radiopharmaceutical Development Pipeline at the 2025 American Association for Cancer Research (AACR) Annual MeetingAbdera Therapeutics will present updates on its radiopharmaceutical pipeline at the 2025 AACR Annual Meeting, including a poster on Phase 1 dosing of ABD-147 for small cell lung cancer and preclinical data for ABD-320. The company plans to advance ABD-320 into clinical development in the first half of 2026.Business Wire BlogAbdera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceAbdera Therapeutics CEO Lori Lyons-Williams will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The company will detail progress on ABD-147, a DLL3-targeted radiopharmaceutical in first-in-human Phase 1 for SCLC and LCNEC, and share preclinical data on ABD-320.YahooFDA grants IND clearance for Abdera’s Phase I cancer therapy trialThe FDA granted IND clearance for Abdera Therapeutics' Phase I trial of ABD-147, a DLL3-targeting radiopharmaceutical for small cell lung cancer and large cell neuroendocrine carcinoma. The first-in-human study will assess efficacy and safety in patients who received platinum-based therapy, with the trial planned for the second half of this year.YahooAbdera Therapeutics Announces FDA Clearance of IND Application for ABD-147Abdera Therapeutics announced FDA clearance of its IND application for ABD-147, a DLL3-targeting radiopharmaceutical for small cell lung cancer and large cell neuroendocrine carcinoma. The company plans to initiate a Phase 1 clinical trial in the second half of 2024. The trial will evaluate safety and preliminary efficacy in patients who previously received platinum-based therapy.Business Wire BlogAbdera Therapeutics Announces FDA Clearance of IND Application for ABD-147Abdera Therapeutics announced FDA clearance of its IND application for ABD-147, a DLL3-targeting radiopharmaceutical for small cell lung cancer and large cell neuroendocrine carcinoma. The company plans to initiate a Phase 1 clinical trial in the second half of 2024. The trial will evaluate safety and preliminary efficacy in patients who previously received platinum-based therapy.